AMO Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AMO Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11024
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AMO Pharma Ltd (Amo Pharma) is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company provides pipeline product portfolio such as AMO-01, and AMO-02. Its AMO-01 is being developed for the treatment of autism and intellectual disabilities. It is an inhibitor of the ras-extracellular signal-regulated kinase pathway (Ras-ERK). AMO Pharma offers AMO-02 which is used for the treatment of myotonic dystrophy, CNS, neuromuscular and oncology indications, among others. It is an inhibitor of glycogen synthase kinase 3 beta. The company provides target therapy areas such as central nervous system disorders, neuromuscular and Steinert’s disease. It also has operations in the US and the UK. Amo Pharma is headquartered in London, the UK.

AMO Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
AMO Pharma Enters into Agreement with Ranedis Pharma 10
Licensing Agreements 11
AMO Pharma Enters into Licensing Agreement with Numedicus 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
Equity Offering 13
AMO Pharma Raises USD25 Million in Financing 13
AMO Pharma Ltd – Key Competitors 14
AMO Pharma Ltd – Key Employees 15
AMO Pharma Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AMO Pharma Enters into Agreement with Ranedis Pharma 10
AMO Pharma Enters into Licensing Agreement with Numedicus 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
AMO Pharma Raises USD25 Million in Financing 13
AMO Pharma Ltd, Key Competitors 14
AMO Pharma Ltd, Key Employees 15
AMO Pharma Ltd, Other Locations 16

List of Figures
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[AMO Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aabar Investments:企業の戦略的SWOT分析
    Aabar Investments - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Tullow Oil plc:戦略・SWOT・企業財務分析
    Tullow Oil plc - Strategy, SWOT and Corporate Finance Report Summary Tullow Oil plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Star Entertainment Group Ltd:企業の戦略・SWOT・財務情報
    The Star Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary The Star Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara) a subsidiary of Takara Holdings Inc, is a biotechnology company engaged in the production and distribution of research reagents and scientific instruments. The company is involved in providing quality research products to life science researchers across the world. It …
  • The Binding Site Group Ltd:製品パイプライン分析
    Summary The Binding Site Group Ltd (Binding Site) is a clinical diagnostic tools supplier that concentrates on research, development, manufacturing and distribution of immunodiagnostic assays. The company’s product portfolio includes antibodies, antigens, bulk antisera, assays for plasma protein ana …
  • Sinovac Biotech Ltd (SVA):企業の財務・戦略的SWOT分析
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, a an inactivated hepatitis A vaccine; bilive, a combined inactivated hepatitis A and B vaccine; anflu, a split viron influenz …
  • Neurosigma Inc:企業の製品パイプライン分析
    Summary Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. It offers Monarch eTNS System for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company off …
  • Mereo Biopharma Group Plc (MPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Lansdowne Oil & Gas plc (LOGP):石油・ガス:M&Aディール及び事業提携情報
    Summary Lansdowne Oil & Gas Plc (Lansdowne Oil & Gas) is an independent oil and gas exploration and production company. The company acquires, explores and develops crude oil and natural gas appraisals in the North Celtic Sea Basin offshore in southern Ireland. It develops Barryroe Field in the North …
  • Hikma Pharmaceuticals Plc (HIK):製薬・医療:M&Aディール及び事業提携情報
    Summary Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and …
  • Sekisui Diagnostics LLC:製品パイプライン分析
    Summary Sekisui Diagnostics LLC (Sekisui Diagnostics), a subsidiary of Sekisui Chemical Co Ltd is a medical device company that develops, manufactures and supplies clinical diagnostic and research products. The company’s products include coagulation, clinical chemistry, virotech products, OSOM rapid …
  • Linamar Corporation:企業の戦略・SWOT・財務情報
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Atlantic Power Corporation (ATP):電力:M&Aディール及び事業提携情報
    Summary Atlantic Power Corporation (Atlantic Power) is an electric utility that owns and operates diversified power generation assets. It produces electricity from various sources including biomass, coal, hydro, and natural gas sources. The company sells power to utilities and other large commercial …
  • Mekonomen AB:企業の戦略・SWOT・財務情報
    Mekonomen AB - Strategy, SWOT and Corporate Finance Report Summary Mekonomen AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Lenovo Group Ltd (992):企業の財務・戦略的SWOT分析
    Lenovo Group Ltd (992) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Enercon Services Inc-エネルギー分野:企業M&A・提携分析
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …
  • Kanika Hotels Public Company Limited:企業の戦略・SWOT・財務分析
    Kanika Hotels Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Kanika Hotels Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Boart Longyear Ltd:企業の戦略・SWOT・財務分析
    Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report Summary Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • John Wood Group Plc (WG.):企業の財務・戦略的SWOT分析
    John Wood Group Plc (WG.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆